利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

51 条记录 (耗时 0.014 秒)

    REAGENTS AND METHODS FOR THE QUANTIFICATION OF IMIPRAMINE OR DESIPRAMINE IN BIOLOGICAL FLUIDS
    35.
    发明授权
    REAGENTS AND METHODS FOR THE QUANTIFICATION OF IMIPRAMINE OR DESIPRAMINE IN BIOLOGICAL FLUIDS 失效
    试剂和方法米帕明地昔帕明或定量生物体液中

    公开(公告)号：EP0641439B1

    公开(公告)日：2000-09-13

    申请号：EP92917086.8

    申请日：1992-07-29

    申请人： ABBOTT LABORATORIES

    发明人： ADAMCZYK, Maciej ,  JOHNSON, Donald ,  HARRINGTON, Charles, A.

    IPC分类号： G01N33/533 ,  G01N33/94 ,  C07D223/28

    CPC分类号： G01N33/533 ,  C07D223/28 ,  G01N33/9466 ,  Y10S436/815 ,  Y10S530/807

    摘要： Immunoassay methods and reagents for the specific quantification of imipramine or desipramine in a test sample are disclosed. The measurement of imipramine or desipramine is accomplished in a specific immunoassay employing antibodies prepared with imipramine or desipramine derivatives of formula (III), wherein P is an immunogenic carrier material, X is two heteroatoms, Y is a linking group comprising from 1 to 6 carbon atoms and P is an immunogenic carrier material, and wherein for imipramine, R is CH3, and for desipramine, R is H. The present invention also describes the synthesis of unique labeled reagents of the structure of formula (IV), wherein Z is a linking group comprising 1 to 4 carbon atoms and 0 to 2 heteroatoms and Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and wherein for imipramine, R1 is CH3, and for desipramine, R1 is H.

    DETERMINATION OF TRICYCLIC ANTIDEPRESSANT DRUGS IN THE PRESENCE OF INTERFERING SUBSTANCES.
    37.
    发明公开
    DETERMINATION OF TRICYCLIC ANTIDEPRESSANT DRUGS IN THE PRESENCE OF INTERFERING SUBSTANCES. 失效
    BESTIMMUNG TRIZYKLISCHER ANTIDEPRESSIVA在GEGENWARTSTÖRENDERSUBSTANZEN。

    公开(公告)号：EP0619020A4

    公开(公告)日：1994-07-07

    申请号：EP92905134

    申请日：1991-12-13

    申请人： ABBOTT LAB

    发明人： ADAMCZYK MACIEJ ,  FISHPAUGH JEFFREY R ,  HARRINGTON CHARLES A ,  HARTTER DARYL E ,  HRUSKA ROBERT E

    IPC分类号： G01N30/06 ,  G01N30/88 ,  G01N30/91 ,  G01N33/542 ,  G01N33/94 ,  G01N33/50 ,  G01N30/02 ,  G01N30/22 ,  G01N33/53

    CPC分类号： G01N33/9466

    摘要： Method and reagents for determining a compound of interest present in a test sample also containing one or more interfering compounds having substantially similar chemical structures, and otherwise analytically indistinguishable from each other, employing a pretreatment reagent capable of selectively modifying the chemical structure of one of the compounds without significantly modifying or altering the chemical structure of the other one of the compounds. The selective modification results in the modified compound having a chemical structure which is substantially dissimilar to the chemical structure of the other one of said compounds wherein the compounds are substantially distinguishable from each other to permit the analytical determination of one or the other of such compounds by immunoassay, high pressure liquid chromatography, and thin layer chromatography techniques, especially for the fluorescent polarization immunoassay determination of tricyclic antidepressant drugs in the presence of phenothiazines.

    摘要翻译： 用于测定存在于测试样品中的感兴趣化合物的方法和试剂，所述测试样品还含有一种或多种干扰化合物，所述干扰化合物具有基本相似的化学结构，并且另外在分析上彼此不可区分，采用能够选择性地改变其中一种化学结构的预处理试剂 化合物没有显着改变或改变另一种化合物的化学结构。 选择性修饰导致修饰化合物具有与所述化合物中另一化合物的化学结构基本不相似的化学结构，其中所述化合物基本上彼此可区分以允许通过以下方式对这些化合物中的一种或另一种进行分析测定： 免疫测定法，高压液相色谱法和薄层色谱法技术，特别是用于吩噻嗪存在下的三环类抗抑郁药物的荧光偏振免疫测定法。

    Serum pretreatment for tricyclic antidepressant drug assays and kit therefor
    39.
    发明公开
    Serum pretreatment for tricyclic antidepressant drug assays and kit therefor 失效
    从三环类抗抑郁药和Reagensätz它确定治疗前血清。

    公开(公告)号：EP0177344A2

    公开(公告)日：1986-04-09

    申请号：EP85307045.6

    申请日：1985-10-02

    申请人： SYNTEX (U.S.A.) INC.

    发明人： Collins, Christine Glen ,  Pankay, Susan ,  Jaklitsch, Anna

    IPC分类号： G01N33/44

    CPC分类号： G01N33/9466 ,  Y10T436/141111

    摘要： Serum is passed through a column containing alkylated silica gel. The column is then washed with a mixture comprising from about 50 to 85 volume percent of an aqueous buffered medium of pH from about 3.5 to 5.0 and from about 15 to 50 volume percent of an organic solvent containing from 1 to 6 carbon atoms and from 1 to 5 heteroatoms selected from oxygen, nitrogen, and sulfur. The tricyclic antidepressant drug is removed from the column with an eluent mixture comprising from about 0 to 75 volume percent of an aqueous buffered medium of pH of about from 6 to 8 and from about 25 to 100 volume percent of one or more organic solvents containing from 1 to 6 carbon atoms and from 1 to 5 heteroatoms selected from oxygen, nitrogen, and sulfur. In this way, a tricyclic antidepressant drug sample, free from interfering metabolites, for use in assay determinations is obtained.